

REMARKS

Claims 1-63 pend; 64-79 are withdrawn.

Various rejections are presented. Applicants respond to same hereby as elucidated in the course of the following discussion.

Objection under 35 USC 132 and Rejection under 35 USC 112 1st Para:

The Official Action contends the amendments made to the specification and Claims 59-62 are constituted of new matter. Specifically, that the substituted "7b" for "1" as chiral denomination is unsupported.

Applicants' correction is proper. It is abundantly clear to the skilled reader that the stereochemistry as amended is duly derivable from the specification. That such an inherent disclosure can serve as basis for support is well known, as is the corollary principle that support need never be recited *in haec verba*.

Withdrawal of the objection/rejection is requested.

Rejection under 35 USC 112, 2d Para:

- Claims 1-63 are rejected on averment that W and Q in formula I are not linked. W and Q are linked, see e.g. Formula I at page 1 of the specification. Applicants provide a clarifying amendment to Claim 1 in this regard. R7 is coincidentally no longer floating.
- Claim 58 is amended to recite said Formula I is that of Claim 1.
- Antecedent support for the "quinoxaline" recitation of Claim 58 is challenged. Without prejudice, disclaimer or acquiescence, applicable deletions have been made to Claim 58.

Rejection under 35 USC 102

Claims 1, 3-5, 9-11, 12, 14, 19, 24, 25, 39, 41, 42, 44, 52, 53 and 55, 56 are allegedly anticipated by WO 97/03066 (Wakabayashi).

The Official Action points *inter alia* to page 8 scheme A-III, compound VIII, of the reference. Said compound VIII has, as a piperidine substituent, the group CO₂Bu^t.

Applicants by this amendment have deleted “CO₂R⁹” from the definition of R³ claim 1, hence the CO₂Bu^t group aforesaid. Said deletion is made without acquiescence to the substance of the rejection and without prejudice or disclaimer to any future prosecution to any species or permutation of same comprising the CO₂R⁹ moiety.

The instant amendment establishes novelty with respect to compound VIII and compounds 11,25, 32, 36, 40, 44, 48, 53, 58, 64, 69, 74, 78, 82, 86, 90, 94 and 98—all of which are identified by the Official Action and all of which contain tert-butoxycarbonyl, now removed from claim 1.

As to compound 37 of Nakahayashi, also noted by the Official Action, applicants reading of same indicates that the substituents thereof corresponding to R⁶ and R⁷ of instant claim 1 are hydrogen. Hydrogen is not recited for R⁶ and R⁷ as claimed.

Applicants submit the claims are novel under § 102 and withdrawal of the instant rejection is requested.

Rejection under 35 USC 103:

- Claims 1-5, 8-25, 30-32, 34-39, 41-52, 55-56 and 58-63 are rejected as obvious given WO 94/13663 (Howard). The Official Action admits that the instant claims are different at least insofar as requiring quinoline -2-one, indoline-2-one or isoquinoline-1-one, for the bicyclic heteroaryl ring. The gravamen of the rejection is, however, that Howard (purportedly) teaches equivalence of its heteroaryl rings with those claimed; ostensibly, substituting one for the other would have been routine.

Applicants rebut the assertion. Attached herewith is a Declaration of Dr. Brian T. O'Neill, an inventor on the instant case (and as it turns, the Howard reference). The declared data firmly establishes the claimed compounds have unexpectedly improved properties relative to Howard. Specifically, 3 compounds representative of Howard were compared against 3 embodiments of the present invention. The comparison of antagonism of substance P is presented using the well-known induced foot tapping test in gerbils, as variously described in Smith et al. Jour. Pharm. Exp. Therap. 298, 3, 1252-1259, 2001; and Rupniak et al. (1995) 116, 1937-1943 British Journal of Pharmacology,

copies of both annexed hereto at Tab A. Effectiveness of a compound at a given concentration is measured as a percentage reduction in foot tapping at elapsed time.

Reference to the Declaration demonstrates that the compounds of the invention outperformed those of Howard. I.e. the inventive compounds caused reversals of 74%, 67% and 100% whereas the best of the represented Howard compounds was 34%. Moreover, not only did the inventive compounds show at least about twice the reversal of Howard (67% versus 34%), but they did so at far lower concentrations: 0.32 mg/kg body weight for the invention as opposed to 1 mg/kg for Howard. This increased efficacy at lower amounts is not foreseen by Howard and stands as convincing evidence to the non-obviousness of the posited substitution.

- Claims 1, 3-5, 8-16, 1920, 24-25, 30, 39, 45, 47, 48 are rejected as obvious over Wakabayashi. In articulating the rejection the Official Action relies on the assessment of compounds given for 102 *supra*.

Applicants observe that compounds VIII and 11, 25, 32, 36, 40, 44, 48, 53, 58, 64, 74, 78, 82, 86, 90, 94 and 98 of Wakabayashi are all intermediates. At law, they are thus unavailable for a rejection under 35 USC 103, see e.g. *In re Lalu*, 223 USPQ 1257 (Fed Cir 1980).

In regard to compound 37, a reading of same indicates that the moieties thereof corresponding to R₃, R₆ and R₇ of claim 1 are all hydrogen. By contrast, R₆ of claim 1 does not recite hydrogen; nor does R₇; and R₃ can not be hydrogen under the circumstances that attend Wakabayashi compound 37 (see proviso (b) of claim 1).

There are thus multiform differences between compound 37 and the claims. Nothing in Wakabayashi would cause one to make the modifications needed to result in the claimed compound; and nothing is offered of record other than *ipse dixit* reasoning, which is legally insufficient.

It is accordingly submitted that the claims are patentable over Howard and Wakabayashi and withdrawal of the rejection under 103 is requested.

A Marked-Up Version of the Claims is annexed hereto.

WHEREFORE, applicants submit the instant case is allowable, passage to which is earnestly solicited.

Respectfully Submitted,

Date: July 7, 2003




Richard L. Catania
Attorney for Applicants
Reg. No. 32,608

Pfizer Inc
Patent Dept., 5th Floor
150 East 42nd Street
New York, NY 10017
(212) 733-6513

Marked-Up Version of the Claims

Please amend Claims 1 and 58 as follows:

1. (amended) A compound of the formula



I

wherein Q is C=NH, C=CH₂, C=S, C=O, SO or SO₂;

A is CH, CH₂, C(C₁-C₆)alkyl, CH(C₁-C₆)alkyl, C(CF₃) or CH(CF₃), with the proviso that when B is present, A must be either CH, C(C₁-C₆)alkyl or C(CF₃);

B is absent or is methylene or ethylene;

each of Y and Z is N or CH, with the proviso that Y and Z can not both be N;

G is NH(CH₂)_q, S(CH₂)_q or O(CH₂)_q, wherein q is zero or one;

with the proviso that when q is zero, G is NH₂, SH or OH;

W is a one carbon linking group (~~i.e. methylene~~) or a saturated or unsaturated two or three carbon linking group, wherein each of the foregoing W groups can optionally be substituted with one substituent R⁷ or two substituents R⁷ and R⁶, or W is a one carbon linking group that forms, together with a 2, 3, 4 or 5 carbon chain, a 3, 4, 5 or 6 membered spiro ring, respectively;

or W is a saturated two carbon chain linking group that forms, together with a separate 1, 2 or 3 carbon chain, a fused 3, 4 or 5 membered ring, respectively;

or W is a saturated two carbon chain linking group, wherein one of the two carbons in the chain forms, together with a separate 2, 3, 4 or 5 carbon chain, a 3, 4, 5 or 6 membered spiro ring, respectively;

p is zero, one or two;

R^3 is selected from hydrogen, COR^9 , CO_2R^9 , optionally substituted phenyl, optionally substituted heterocyclic rings, and optionally substituted (C_1-C_8) alkyl wherein one of the CH_2 groups of said (C_1-C_8) alkyl may optionally be replaced with a sulfur, oxygen or carbonyl group and wherein said (C_1-C_8) alkyl can optionally be substituted with from one to three substituents, preferably with zero substituents or one substituent, independently selected from hydroxy, oxo, phenyl- (C_1-C_3) alkoxy, phenyl, cyano, halo, optionally substituted heterocyclic rings, NR^9COR^{10} , $NR^9CO_2R^{10}$, $CONR^9R^{10}$, COR^9 , CO_2R^9 , NR^9R^{10} , and (C_1-C_6) alkoxy optionally substituted with from one to seven fluorine atoms, preferably with from zero to three fluorine atoms;

and wherein the heterocyclic rings of R^3 and the heterocyclic ring substituents on the alkyl groups of R^3 are selected, independently, from 3 to 7 membered saturated or unsaturated monocyclic rings containing from 1 to 4 ring heteroatoms, and 8 to 12 membered saturated or unsaturated bicyclic rings containing from 1 to 4 ring heteroatoms, wherein said heteroatoms are selected, independently, from oxygen, nitrogen and sulfur, with the proviso that there can not be two adjacent ring oxygen atoms or two adjacent ring sulfur atoms in either the monocyclic or bicyclic heterocyclic rings, and with the proviso that heterocyclic rings formed from NR^9R^{10} or $CONR^9R^{10}$ must contain at least one nitrogen atom;

and wherein the heterocyclic rings of R^3 and the heterocyclic ring substituents on the alkyl groups of R^3 can optionally be substituted with one or more substituents, preferably with zero, one or two substituents, independently selected from oxo, hydroxy, thioxo, halo, cyano, phenyl, $(CH_2)_mNR^9R^{10}$, NR^9COR^{10} , $(CH_2)_mOR^9$, wherein m is zero, one or two, and (C_1-C_6) alkyl optionally substituted with one or

more substituents, preferably with from zero to two substituents, independently selected from halo, CF_3 , methoxy and phenyl;

and wherein the phenyl groups of R^3 and the phenyl substituents in the alkyl groups of R^3 can optionally be substituted with one or more substituents, preferably with from zero to two substituents, independently selected from the group consisting of halo, cyano, nitro, CF_3 , $(\text{CH}_2)_m\text{NR}^9\text{R}^{10}$, wherein m is zero, one or two, $\text{NR}^9\text{COR}^{10}$, $\text{NR}^9\text{CO}_2\text{R}^{10}$, $\text{CONR}^9\text{R}^{10}$, $\text{CO}_2\text{NR}^9\text{R}^{10}$, COR^9 , CO_2R^9 , $(\text{C}_1\text{-C}_6)\text{alkyl}$ optionally substituted with from one to seven fluorine atoms, preferably with from zero to three fluorine atoms, $(\text{C}_1\text{-C}_6)\text{alkoxy}$ optionally substituted with from one to seven fluorine atoms, preferably with from zero to three fluorine atoms, and $(\text{C}_2\text{-C}_6)\text{alkenyl}$ optionally substituted with from one to seven fluorine atoms, preferably with from zero to three fluorine atoms;

each of R^1 , R^2 , R^{11} , R^{12} and R^{13} are selected, independently, from hydrogen and $(\text{C}_1\text{-C}_6)\text{alkyl}$ optionally substituted with one or more substituents, preferably with zero, one or two substituents, that are selected, independently, from hydroxy, oxo, $(\text{C}_1\text{-C}_6)\text{alkoxy}$ and cyano;

or R^1 and R^2 , together with the carbon atoms to which they are attached, or R^2 and R^3 , together with the carbon and nitrogen to which they are attached, respectively, form a 5 or 6 membered saturated heterocyclic ring containing one or two heteroatoms that are selected, independently, from nitrogen, oxygen and sulfur, with the proviso that said ring can not contain two adjacent oxygen atoms or two adjacent sulfur atoms; or R^1 and R^2 , together with the carbons to which they are attached, form a 5 or 6 membered, saturated or unsaturated carbocyclic ring, and wherein said heterocyclic and carbocyclic rings formed by R^1 and R^2 or by R^2 and R^3 can be substituted with one or more substituents, preferably with zero substituents or one substituent, independently selected from halo, oxo, NR^9R^{10} , $(\text{C}_1\text{-C}_6)\text{alkyl}$ optionally substituted with from one to seven fluorine atoms, preferably with from zero to three fluorine atoms, and $(\text{C}_1\text{-C}_6)\text{alkoxy}$ optionally substituted with from one to seven fluorine atoms, preferably with from zero to three fluorine atoms;

or R^{12} and R^{13} , together with the carbon atoms to which they are attached, form a 5 or 6 membered saturated heterocyclic ring containing one or two heteroatoms that are selected, independently, from nitrogen, oxygen and sulfur, with the proviso that said ring can not contain two adjacent oxygen atoms or two adjacent sulfur atoms, or R^{12} and R^{13} , together with the carbons to which they are attached, form a 5 or 6 membered, saturated or unsaturated carbocyclic ring, and wherein said heterocyclic and carbocyclic rings formed by R^{12} and R^{13} can be substituted with one or more substituents, preferably with zero substituents or one substituent, independently selected from NR^9R^{10} , halo, phenyl-S-, phenyl-SO-, phenyl-SO₂-, oxo, (C₁-C₆)alkoxy optionally substituted with from one to seven fluorine atoms, preferably with from zero to three fluorine atoms, and (C₁-C₆)alkyl optionally substituted with from one to seven fluorine atoms, preferably with from zero to three fluorine atoms:

with the proviso that no more than one of R^1 and R^2 , R^2 and R^3 , and R^{12} and R^{13} can form a ring;

R^4 is selected from phenyl, 2-, 3- or 4-pyridyl, 2- or 3-thienyl, and pyrimidyl, wherein R^4 can be optionally substituted with one or more substituents, preferably with zero or one substituent, selected, independently, from halo, (C₁-C₆)alkyl optionally substituted with from one to seven fluorine atoms, preferably with from zero to three fluorine atoms, (C₁-C₆)alkoxy optionally substituted with from one to seven fluorine atoms, preferably with from zero to three fluorine atoms, and (C₂-C₆) alkenyl optionally substituted with from one to seven fluorine atoms, preferably with from zero to three fluorine atoms;

R^5 and R^8 are selected, independently, from hydrogen, -SO(C₁-C₆)alkyl, -SO₂-(C₁-C₆)alkyl, -SO-aryl, -SO₂-aryl, CF₃, halo, phenyl, phenyl-(C₁-C₂)alkyl, hydroxy, aryloxy, heteroaryloxy, pyridyl, tetrazolyl, oxazolyl, thiazolyl, (C₁-C₆)alkoxy optionally substituted with from one to seven fluorine atoms, preferably with from zero to three fluorine atoms, (C₁-C₆)alkyl optionally substituted with from one to seven fluorine atoms, preferably with from zero to three fluorine atoms, and (C₁-C₆)alkyl substituted with one or more substituents, preferably with from zero to two substituents selected, independently,

from hydroxy, oxo, (C₁-C₆)alkoxy, phenyl-(C₁-C₃)alkoxy, phenyl, cyano, chloro, bromo, iodo, NR⁹R¹⁰, NR⁹COR¹⁰, NR⁹CO₂R¹⁰, CONR⁹R¹⁰, COR⁹ and CO₂R⁹;

R⁶ and R⁷ are selected, independently, from -SO(C₁-C₆)alkyl, -SO₂-(C₁-C₆)alkyl, -SO-aryl, -SO₂-aryl, CF₃, halo, phenyl, phenyl-(C₁-C₂)alkyl, hydroxy, aryloxy, heteroaryloxy, pyridyl, tetrazolyl, oxazolyl, thiazolyl, (C₁-C₆)alkoxy optionally substituted with from one to seven fluorine atoms, preferably with from zero to three fluorine atoms, (C₁-C₆)alkyl optionally substituted with from one to seven fluorine atoms, preferably with from zero to three fluorine atoms, and (C₁-C₆)alkyl substituted with one or more substituents, preferably with from zero to two substituents selected, independently, from hydroxy, oxo, (C₁-C₆)alkoxy, phenyl-(C₁-C₃)alkoxy, phenyl, cyano, chloro, bromo, iodo, NR⁹R¹⁰, NR⁹COR¹⁰, NR⁹CO₂R¹⁰, CONR⁹R¹⁰, COR⁹ and CO₂R⁹;

each R⁹ and each R¹⁰ is selected, independently, from hydrogen, (C₁-C₆)alkyl, hydroxy(C₁-C₆)alkyl, phenyl and CF₃;

or R⁹ and R¹⁰, when R³ is NR⁹R¹⁰ or CONR⁹R¹⁰, can form, together with the nitrogen to which they are attached, an optionally substituted heterocyclic ring that contains at least one nitrogen atom;

and wherein the phenyl groups in the definition of R⁵, R⁶, R⁷ and R⁸ and the phenyl moiety of phenyl (C₁-C₂)alkyl in the definition of R⁵, R⁶, R⁷ and R⁸ can optionally be substituted with one or more substituents, preferably with from zero to two substituents, that are selected, independently, from halo, hydroxy, (C₁-C₆)alkoxy optionally substituted with from one to seven fluorine atoms, preferably with from zero to three fluorine atoms, and (C₁-C₆)alkyl optionally substituted with from one to seven fluorine atoms, preferably with from zero to three fluorine atoms;

with the proviso that: (a) R⁸ can not be halo, hydroxy, cyano, aryloxy, heteroaryloxy, substituted or unsubstituted (C₁-C₆)alkoxy or methyl substituted with from 1-3 fluorine atoms; and (b) when Q is C=O or C=S, and Y and Z are both carbon, and W is a methylene, ethylene or propylene group that is optionally substituted with (C₁-C₆)alkyl or fluoro substituted (C₁-C₆)alkyl, and all of R¹, R², R¹¹, R¹² and R¹³ are hydrogen, and R⁵, R⁶, R⁷, and R⁸ are selected from hydrogen, halo, (C₁-C₆) alkyl optionally substituted with

from 1 to 7 fluorine atoms, (C₁-C₆) alkoxy optionally substituted with from 1 to 7 fluorine atoms, then R³ can not be hydrogen;

or a pharmaceutically acceptable salt thereof.

58. (amended) A compound that is selected from isomers and mixtures of isomers of the following compounds, wherein said isomers or mixtures of isomers have the stereochemistry depicted in structural of claim 1 formula I:

7-[(1-Dimethylaminoacetyl-2-phenyl-piperidin-3-ylamino)-methyl]-6-methoxy-1-methyl-3,4-dihydro-1H-quinolin-2-one;

6-Methoxy-1-methyl-7-{[2-phenyl-1-(pyridin-2-yl-acetyl)-piperidin-3-ylamino]-methyl}-3,4-dihydro-1H-quinolin-2-one;

6-Methoxy-1-methyl-7-{[2-phenyl-1-(pyridin-3-yl-acetyl)-piperidin-3-ylamino]-methyl}-3,4-dihydro-1H-quinolin-2-one;

6-Methoxy-1-methyl-7-{[2-phenyl-1-(pyridin-4-yl-acetyl)-piperidin-3-ylamino]-methyl}-3,4-dihydro-1H-quinolin-2-one;

6-Cyclopropoxy-1-methyl-7-[(2-phenyl-piperidin-3-ylamino)-methyl]-3,4-dihydro-1H-quinolin-2-one;

(5-Chloro-2-methoxy-benzyl)-(2-phenyl-octahydro-cyclopenta[b]pyrrol-3-yl)-amine;

6-Methoxy-1-methyl-7-[(1-[1,2,4]oxadiazol-3-ylmethyl-2-phenyl-piperidin-3-ylamino)-methyl]-3,4-dihydro-1H-quinolin-2-one;

7-{{1-(Imidazol-1-yl-acetyl)-2-phenyl-piperidin-3-ylamino}-methyl}-6-methoxy-1-methyl-3,4-dihydro-1H-quinolin-2-one;

1-[3-(2-Methoxy-5-trifluoromethoxy-benzylamino)-2-phenyl-piperidin-1-yl]-2-pyridin-2-yl-ethanone;

1-[3-(2-Methoxy-5-trifluoromethoxy-benzylamino)-2-phenyl-piperidin-1-yl]-2-pyridin-3-yl-ethanone;

1-[3-(2-Methoxy-5-trifluoromethoxy-benzylamino)-2-phenyl-piperidin-1-yl]-2-pyridin-4-yl-ethanone;

2-Imidazol-1-yl-1-[3-(2-methoxy-5-trifluoromethoxy-benzylamino)-2-phenyl-piperidin-1-yl]-ethanone;

2-Dimethylamino-1-[3-(2-methoxy-5-trifluoromethoxy-benzylamino)-2-phenyl-piperidin-1-yl]-ethanone

3-(2-Benzylloxy-5-trifluoromethoxy-phenyl)-6-phenyl-1-oxa-7-aza-spiro[4.5]decane;

1-[3-(2-Methoxy-5-trifluoromethoxy-benzylamino)-2-phenyl-piperidin-1-yl]-2-pyrrolidin-1-yl-ethanone;

(2-Methoxy-5-trifluoromethoxy-benzyl)-(1-[1,2,4]oxadiazol-3-ylmethyl-2-phenyl-piperidin-3-yl)-amine;

7-{[2-(4-Fluoro-phenyl)-piperidin-3-ylamino]-methyl}-6-methoxy-1-methyl-3,4-dihydro-1H-quinolin-2-one;

[1-(2-Imidazol-1-yl-ethyl)-2-phenyl-piperidin-3-yl]-(2-methoxy-5-trifluoromethoxy-benzyl)-amine;

7-{[1-(2-Dimethylamino-ethyl)-2-phenyl-piperidin-3-ylamino]-methyl}-6-methoxy-1-methyl-3,4-dihydro-1H-quinolin-2-one;

(5-Chloro-2-ethoxy-pyridin-3-ylmethyl)-(2-phenyl-piperidin-3-yl)-amine;

(5-Chloro-2-methoxy-pyridin-3-ylmethyl)-(2-phenyl-piperidin-3-yl)-amine;

Dibenzofuran-2-ylmethyl-(2-phenyl-piperidin-3-yl)-amine;

[3-(Indan-2-yloxy)-4-methoxy-benzyl]-(2-phenyl-piperidin-3-yl)-amine;

6-[(2-Phenyl-piperidin-3-ylamino)-methyl]-chroman-4-one;

(5-Methyl-benzo[b]thiophen-3-ylmethyl)-(2-phenyl-piperidin-3-yl)-amine;

(2,2-Dimethyl-chroman-6-ylmethyl)-(2-phenyl-piperidin-3-yl)-amine;

(1H-Benzoimidazol-5-ylmethyl)-(2-phenyl-piperidin-3-yl)-amine;

1-{2-[(2-Phenyl-piperidin-3-ylamino)-methyl]-phenyl}-pyrrolidin-2-one;

(2-Phenyl-piperidin-3-yl)-[3-(pyridin-2-yloxy)-benzyl]-amine

[3-(4-Methoxy-phenoxy)-benzyl]-(2-phenyl-piperidin-3-yl)-amine;

(4-Phenoxy-benzyl)-(2-phenyl-piperidin-3-yl)-amine;

(2-Phenyl-piperidin-3-yl)-thiophen-2-ylmethyl-amine;

Furan-2-ylmethyl-(2-phenyl-piperidin-3-yl)-amine;

(5-Methyl-furan-2-ylmethyl)-(2-phenyl-piperidin-3-yl)-amine;
 (3-Methyl-thiophen-2-ylmethyl)-(2-phenyl-piperidin-3-yl)-amine;
 (2-Phenyl-piperidin-3-yl)-thiophen-3-ylmethyl-amine;
 (3-Methyl-benzo[b]thiophen-2-ylmethyl)-(2-phenyl-piperidin-3-yl)-amine;
 Benzofuran-2-ylmethyl-(2-phenyl-piperidin-3-yl)-amine;
 (5-Ethyl-furan-2-ylmethyl)-(2-phenyl-piperidin-3-yl)-amine;
 (5-Chloro-3-methyl-1-phenyl-1H-pyrazol-4-ylmethyl)-(2-phenyl-piperidin-3-yl)-amine;
 6-Methoxy-7-[[1-(2-methoxy-ethyl)-2-phenyl-piperidin-3-ylamino]-methyl]-1-methyl-3,4-dihydro-1H-quinolin-2-one;
 (5-Methyl-3-phenyl-isoxazol-4-ylmethyl)-(2-phenyl-piperidin-3-yl)-amine;
 (3-Phenoxy-benzyl)-(2-phenyl-piperidin-3-yl)-amine;
 Furan-3-ylmethyl-(2-phenyl-piperidin-3-yl)-amine;
 (3,5-Dimethyl-1-phenyl-1H-pyrazol-4-ylmethyl)-(2-phenyl-piperidin-3-yl)-amine;
 (5,7-Dimethoxy-1H-indol-4-ylmethyl)-(2-phenyl-piperidin-3-yl)-amine;
 (5-Methoxy-1H-indol-3-ylmethyl)-(2-phenyl-piperidin-3-yl)-amine;
~~(4-Oxy-quinoxalin-2-ylmethyl)-(2-phenyl-piperidin-3-yl)-amine;~~
~~(2-Phenyl-piperidin-3-yl)-quinoxalin-2-ylmethyl-amine;~~
 7-[[1-(2,3-Dihydroxy-propyl)-2-phenyl-piperidin-3-ylamino]-methyl]-6-methoxy-1-methyl-3,4-dihydro-1H-quinolin-2-one;
 (2-Methoxy-5-trifluoromethoxy-benzyl)-[2-phenyl-1-(2-pyrrolidin-1-yl-ethyl)-piperidin-3-yl]-amine;
 6-Ethoxy-1-methyl-7-[(2-phenyl-piperidin-3-ylamino)-methyl]-3,4-dihydro-1H-quinolin-2-one;
 [1-(2-Dimethylamino-ethyl)-2-phenyl-piperidin-3-yl]-(2-methoxy-5-trifluoromethoxy-benzyl)-amine;
 3-(2-Cyclopropoxy-5-trifluoromethoxy-phenyl)-6-phenyl-1-oxa-7-aza-spiro[4.5]decane;
 [1-(2-Methoxy-ethyl)-2-phenyl-piperidin-3-yl]-(2-methoxy-5-trifluoromethoxy-benzyl)-amine;

6-Hydroxy-1-methyl-7-[(2-phenyl-piperidin-3-ylamino)-methyl]-3,4-dihydro-1H-quinolin-2-one;

6-Methoxy-1-methyl-7-[(2-phenyl-octahydro-cyclopenta[b]pyrrol-3-ylamino)-methyl]-3,4-dihydro-1H-quinolin-2-one;

7-{[2-(4-Fluoro-phenyl)-piperidin-3-ylamino]-methyl}-6-methoxy-3,4-dihydro-1H-quinolin-2-one;

6-Methoxy-1-methyl-7-(6-phenyl-1-oxa-7-aza-spiro[4.5]dec-3-yl)-3,4-dihydro-1H-quinolin-2-one;

6-Methoxy-1,3,3-trimethyl-5-[(2-phenyl-octahydro-cyclopenta[b]pyrrol-3-ylamino)-methyl]-1,3-dihydro-indol-2-one;

[3-Chloro-2-(4-fluoro-phenoxy)-pyridin-4-ylmethyl]-(2-phenyl-piperidin-3-yl)-amine;

6-Ethoxy-1,3,3-trimethyl-5-[(2-phenyl-piperidin-3-ylamino)-methyl]-1,3-dihydro-indol-2-one;

6-Ethoxy-1,3,3-trimethyl-5-[(2-phenyl-octahydro-cyclopenta[b]pyrrol-3-ylamino)-methyl]-1,3-dihydro-indol-2-one;

6-Isopropoxy-1,3,3-trimethyl-5-[(2-phenyl-piperidin-3-ylamino)-methyl]-1,3-dihydro-indol-2-one;

6-Isopropoxy-1,3,3-trimethyl-5-[(2-phenyl-octahydro-cyclopenta[b]pyrrol-3-ylamino)-methyl]-1,3-dihydro-indol-2-one;

6-Ethoxy-1,3,3-trimethyl-5-[(2-phenyl-octahydro-cyclopenta[b]pyrrol-3-ylamino)-methyl]-1,3-dihydro-indol-2-one;

6-Isopropoxy-1,3,3-trimethyl-5-[(2-phenyl-octahydro-cyclopenta[b]pyrrol-3-ylamino)-methyl]-1,3-dihydro-indol-2-one;

7-Isopropoxy-1-methyl-6-[(2-phenyl-piperidin-3-ylamino)-methyl]-3,4-dihydro-1H-quinolin-2-one;

6-Methoxy-1-methyl-7-[(6-methyl-2-phenyl-piperidin-3-ylamino)-methyl]-3,4-dihydro-1H-quinolin-2-one;

6-Methoxy-1,3,3-trimethyl-7-[(2-phenyl-piperidin-3-ylamino)-methyl]-3,4-dihydro-1H-quinolin-2-one;

6-Methoxy-1,3-dimethyl-7-[(2-phenyl-piperidin-3-ylamino)-methyl]-3,4-dihydro-1H-quinolin-2-one;

6-Methoxy-1,3-dimethyl-5-[(2-phenyl-piperidin-3-ylamino)-methyl]-1,3-dihydro-indol-2-one;

6-Methoxy-1-methyl-5-[(2-phenyl-piperidin-3-ylamino)-methyl]-1,3-dihydro-indol-2-one;

5-[(1-Isopropyl-2-phenyl-piperidin-3-ylamino)-methyl]-6-methoxy-1,3,3-trimethyl-1,3-dihydro-indol-2-one;

6-Methoxy-1-methyl-7-[(2-phenyl-1-propyl-piperidin-3-ylamino)-methyl]-3,4-dihydro-1H-quinolin-2-one;

6-Methoxy-1-methyl-7-[[1-(5-methyl-3H-imidazol-4-ylmethyl)-2-phenyl-piperidin-3-ylamino]-methyl]-3,4-dihydro-1H-quinolin-2-one;

7-[[1-(1H-Imidazol-4-ylmethyl)-2-phenyl-piperidin-3-ylamino]-methyl]-6-methoxy-1-methyl-3,4-dihydro-1H-quinolin-2-one;

7-[(1-Isopropyl-2-phenyl-piperidin-3-ylamino)-methyl]-6-methoxy-1-methyl-3,4-dihydro-1H-quinolin-2-one;

6-Methoxy-1,3-dimethyl-7-[(1-methyl-2-phenyl-piperidin-3-ylamino)-methyl]-3,4-dihydro-1H-quinolin-2-one;

5-[(1-Isopropyl-2-phenyl-piperidin-3-ylamino)-methyl]-6-methoxy-1,3,3-trimethyl-1,3-dihydro-indol-2-one;

6-Methoxy-1-methyl-7-[[1-(5-oxo-2,5-dihydro-1H-[1,2,4]triazol-3-ylmethyl)-2-phenyl-piperidin-3-ylamino]-methyl]-3,4-dihydro-1H-quinolin-2-one;

6-Methoxy-7-[(2-phenyl-piperidin-3-ylamino)-methyl]-3,4-dihydro-1H-quinolin-2-one;

1-Ethyl-6-methoxy-7-[(2-phenyl-piperidin-3-ylamino)-methyl]-3,4-dihydro-1H-quinolin-2-one;

1-Methanesulfonyl-6-methoxy-7-[(2-phenyl-piperidin-3-ylamino)-methyl]-3,4-dihydro-1H-quinolin-2-one;

6-Methoxy-1,4,4-trimethyl-7-[(2-phenyl-piperidin-3-ylamino)-methyl]-3,4-dihydro-1H-quinolin-2-one;

8-Fluoro-6-methoxy-1,4,4-trimethyl-7-[(2-phenyl-piperidin-3-ylamino)-methyl]-3,4-dihydro-1H-quinolin-2-one;

6-Methoxy-1-methyl-7-[(2-phenyl-piperidin-3-ylamino)-methyl]-3,4-dihydro-1H-quinolin-2-one;

6-Methoxy-1,4-dimethyl-7-[(2-phenyl-piperidin-3-ylamino)-methyl]-3,4-dihydro-1H-quinolin-2-one;

6-Methoxy-2-methyl-7-[(2-phenyl-piperidin-3-ylamino)-methyl]-3,4-dihydro-2H-isoquinolin-1-one;

6-Methoxy-3-methyl-5-[(2-phenyl-piperidin-3-ylamino)-methyl]-1,1a,3,7b-tetrahydro-3-aza-cyclopropa[a]naphthalen-2-one;

6-Methoxy-1-methyl-,3,3-cyclopropyl-5-[(2-phenyl-piperidin-3-ylamino)-methyl]-1,3-dihydro-indol-2-one;

5-Methoxy-1-methyl-,3,3-cyclopropyl-6-[(2-phenyl-piperidin-3-ylamino)-methyl]-1,3-dihydro-indol-2-one;

6-Methoxy-1-methyl-(6-phenyl-1,7-diaza-spiro[4.5]dec-3-yl)-3,4-dihydro-1H-quinolin-2-one;

6-Methoxy-1-methyl-7-phenyl-1,7-diaza-spiro[4.5]dec-3-yl)-3,4-dihydro-1H-quinolin-2-one;

6-Methoxy-3-methyl-5-[(1-phenyl-8-aza-bicyclo[3.2.1]oct-2-ylamino)-methyl] 1,1a,3,7b-tetrahydro-3-aza-cyclopropa[a]naphthalen-2-one;

(6-Methoxy-1-methyl-2,2-dioxo-1,2,3,4-tetrahydro-2-thiobenzo[c [1,2]thiazin-7-yl-methyl)- (2-phenyl-piperidin-3-yl)-amine;

6-Methoxy-3-methyl-5-[(6-methyl-2-phenyl-piperidin-3-ylamino)-methyl]-1,1a,3,7b-tetrahydro-3-aza-cyclopropa[a]naphthalen-2-one;

6-Methoxy-1-methyl-7-(6-phenyl-1,7-diaza-spiro[4.5]dec-3-yl)-3,4-dihydro-1H-quinolin-2-one;

6-Methoxy-1,3,3-trimethyl-5-[(2-phenyl-piperidin-3-ylamino)-methyl]-1,3-dihydro-pyrrolo[2,3-b]pyridin-2-one;

5-Methoxy-1,3,3-trimethyl-6-[(2-phenyl-piperidin-3-ylamino)-methyl]-1,3-dihydro-pyrrolo[3,2-b]pyridin-2-one;

6-Methoxy-1-methyl-7-[(2-phenyl-piperidin-3-ylamino)-methyl]-3,4-dihydro-1H-[1,5]naphthyridin-2-one;

7-[(6-Ethyl-2-phenyl-piperidin-3-ylamino)-methyl]-6-methoxy-1-methyl-3,4-dihydro-1H-quinolin-2-one;

5-[(6-Ethyl-2-phenyl-piperidin-3-ylamino)-methyl]-6-methoxy-1,3,3-trimethyl-1,3,-dihydro-indol-2-one;

6-Methoxy-1,3,3-trimethyl-5-[(2-phenyl-piperidin-3-ylamino)-methyl]-1,3-dihydro-pyrrolo[2,3-b]pyridin-2-one;

5-Methoxy-1,3,3-trimethyl-6-[(2-phenyl-piperidin-3-ylamino)-methyl]-1,3-dihydro-pyrrolo[3,2-b]pyridin-2-one;

6-Methoxy-1-methyl-7-[(2-phenyl-piperidin-3-ylamino)-methyl]-3,4-dihydro-1H-[1,5]naphthyridin-2-one;

6-Methoxy-1-methyl-7-[(6-methyl-2-phenyl-piperidin-3-ylamino)-methyl]-3,4-dihydro-1H-[1,5]naphthyridin-2-one;

7-[(6-Ethyl-2-phenyl-piperidin-3-ylamino)-methyl]-6-methoxy-1-methyl-3,4-dihydro-1H-[1,5]naphthyridin-2-one;

6-Methoxy-1-methyl-7-[(2-phenyl-6-propyl-piperidin-3-ylamino)-methyl]-3,4-dihydro-1H-[1,5]naphthyridin-2-one;

6-Methoxy-3-methyl-5-[(6-methyl-2-phenyl-piperidin-3-ylamino)-methyl]-1,1a,3,7b-tetrahydro-3-aza-cyclopropa[a]naphthalen-2-one;

6-Methoxy-1-methyl-7-(6-phenyl-1,7-diaza-spiro[4.5]dec-3-yl)-3,4-dihydro-1H-quinolin-2-one;

and pharmaceutically acceptable salts thereof.